China pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says
Key takeaways
- China pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says.
- SHANGHAI, May 26 (Reuters) - China s booming pharmaceutical industry is not being impacted by Beijing s tightening scrutiny over deals involving sensitive technologies, the CEO of JW Therapeutics said Tuesday.
- But last month, China ordered U.S. tech giant Meta to unwind its $2 billion-plus acquisition of AI startup Manus, as Beijing tightens scrutiny of U.S.
China pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says. An employee works on a production line manufacturing cold medicine at a workshop during an organised media tour at Youcare Pharmaceutical Group, in Beijing, China January 10, 2023. REUTERS/Tingshu Wang · Reuters By Andrew Silver Tue, May 26, 2026 at 6:51 PM GMT+7 1 min read META By Andrew Silver
SHANGHAI, May 26 (Reuters) - China s booming pharmaceutical industry is not being impacted by Beijing s tightening scrutiny over deals involving sensitive technologies, the CEO of JW Therapeutics said Tuesday.
Global drugmakers are stepping up their search for China‑developed experimental medicines as they cut costs ahead of patent expirations, with industry analysts predicting biotech licensing deals would surge to a fresh record this year.